We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$186M
AUM Growth
+$24.6M
Cap. Flow
+$12.5M
Cap. Flow %
6.76%
Top 10 Hldgs %
43.12%
Holding
83
New
10
Increased
18
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$4.09M
2
ZGNX
Zogenix, Inc.
ZGNX
+$3.14M
3
LOXO
Loxo Oncology, Inc
LOXO
+$2.82M
4
SAGE
Sage Therapeutics
SAGE
+$2.79M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.06M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.85M
2
QURE icon
uniQure
QURE
+$1.68M
3
PODD icon
Insulet
PODD
+$1.64M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$1.48M
5
ONC
BeOne Medicines Ltd
ONC
+$961K

Sector Composition

Rank Sector Weight
1 Healthcare 82.51%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DERM
26
DELISTED
Dermira, Inc.
DERM
$2.39M 1.29%
86,000
+10,500
+14% +$278K
PODD icon
27
Insulet
PODD
$11.4B
$2.24M 1.21%
32,484
-25,000
-43% -$1.64M
FOMX
28
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.12M 1.14%
352,741
+94,074
+36% +$566K
AKBA icon
29
Akebia Therapeutics
AKBA
$343M
$2.02M 1.09%
135,738
– –
SYRE icon
30
Spyre Therapeutics
SYRE
$8.69B
$1.89M 1.02%
13,984
– –
ARDX icon
31
Ardelyx
ARDX
$1.25B
$1.81M 0.98%
275,059
-50,350
-15% -$298K
KURA icon
32
Kura Oncology
KURA
$901M
$1.79M 0.97%
117,281
+11,422
+11% +$168K
RDUS
33
DELISTED
Radius Health, Inc.
RDUS
$1.69M 0.91%
53,309
– –
AGTC
34
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.52M 0.82%
421,000
– –
CDTX
35
DELISTED
Cidara Therapeutics
CDTX
$1.47M 0.79%
10,820
+397
+4% +$60.2K
NGNE icon
36
Neurogene
NGNE
$691M
$1.4M 0.75%
5,946
+1,969
+50% +$461K
EXAC
37
DELISTED
Exactech Inc
EXAC
$1.36M 0.73%
27,532
– –
JNJ icon
38
Johnson & Johnson
JNJ
$641B
$1.31M 0.71%
9,400
– –
IMDZ
39
DELISTED
Immune Design Corp.
IMDZ
$1.28M 0.69%
+328,500
New +$1.79M
SCPH
40
DELISTED
scPharmaceuticals
SCPH
$1.19M 0.64%
+98,100
New +$1.38M
SCYX icon
41
SCYNEXIS
SCYX
$35.5M
$1.18M 0.63%
6,336
– –
ARQL
42
DELISTED
Arqule Inc
ARQL
$1.15M 0.62%
697,192
+269,714
+63% +$350K
TVRD
43
Tvardi Therapeutics
TVRD
$23.8M
$1.15M 0.62%
2,606
– –
CMTA
44
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$1.14M 0.61%
60,000
– –
STXS icon
45
Stereotaxis
STXS
$130M
$1.1M 0.59%
1,372,862
– –
XENE icon
46
Xenon Pharmaceuticals
XENE
$6.36B
$1.07M 0.57%
377,695
– –
NERV icon
47
Minerva Neurosciences
NERV
$196M
$1.03M 0.56%
21,387
– –
CGNT
48
DELISTED
Cogentix Medical, Inc.
CGNT
$1.02M 0.55%
323,482
– –
PRQR icon
49
ProQR Therapeutics
PRQR
$244M
$744K 0.4%
+230,770
New +$829K
ADXS
50
DELISTED
Advaxis Inc
ADXS
$701K 0.38%
16,467
– –
1
2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, DAFNA Capital Management held 83 positions worth $186M, up 15% from $161M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

DAFNA Capital Management deployed $12.5M of net new capital in Q4 2017, opening 10 new positions and adding to 18 existing holdings. Its largest new stake was VBI Vaccines, Inc. New Common Stock (Canada): 33,267 shares worth $4.26M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 80% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $1.85M trimmed.

  • DAFNA Capital Management's largest Q4 2017 buy was VBI Vaccines, Inc. New Common Stock (Canada): 33,267 shares worth $4.26M.
  • DAFNA Capital Management added most to Zogenix, Inc. in Q4 2017, an estimated $3.14M increase.
  • DAFNA Capital Management's biggest Q4 2017 reduction was Immunomedics Inc, cutting an estimated $1.85M.
  • DAFNA Capital Management fully exited uniQure in Q4 2017, selling an estimated $1.68M.
  • DAFNA Capital Management's ten largest holdings make up 43% of its $186M portfolio in Q4 2017.
  • DAFNA Capital Management opened 10 new positions and closed 11 in Q4 2017.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $186M.

Based on DAFNA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.